Boehringer Ingelheim

Main Sponsor

Web Boehringer Ingelheim website
Boehringer Ingelheim

When it comes to outsmarting cancer, we believe we’re brighter together. Guided by a commitment to evidence-based practice and integrity in research, we’re proud of our collaborative research approach that is dedicated to shedding light on the unsolved problems in oncology and improving lives for patients with cancer.

Through scientific innovation and collaboration, Boehringer Ingelheim is committed to discovering and developing novel anti-cancer agents that address unmet needs across a broad range of solid and haematological malignancies. We’re driven by a passion to improve the lives of patients who are battling cancer and a determination for cancer to eventually be treated as a chronic condition. Two agents are currently approved in many countries for specific NSCLC sub-types and the oncology portfolio is supported by a strong early pipeline. As part of a unique research approach, our active partnering strategy aims to further strengthen our presence in this key therapeutic area.

Boehringer Ingelheim in Oncology

Let's Collaborate Logo Boeringher Ingelheim

The ‘Let’s Collaborate’ initiative launched by Boehringer Ingelheim in Oncology is the guiding ethos directing the company’s commitment to oncology and to improving the future of cancer patients. This principle recognises that collaboration is fundamental to making a difference to patients’ lives. Working together connects, potentiates and enhances ideas, research and education. “Let’s Learn”, an extension of this initiative, is an invitation to all healthcare professionals working in oncology to share experiences, exchange ideas, and learn together, in order to advance the common goal of improving the outlook for cancer patients.

Follow Boehringer Ingelheim on social media!

Follow us on Facebook

Follow us on Youtube

Follow us on Twitter

Multimedia from congresses

Boeringher Ingelheim Resources Logo

Find the latest Boehringer Ingelheim resources to come out of major international oncology conferences, and learn more about the LUX and LUME series of clinical trials.

ELCC 2016 Industry Satellite Symposium

Current Insights Perspectives NSCLC Treatment

PILC 2016 Industry Satellite Symposium

Current Insights Perspectives NSCLC Treatment

MedEd resources from Boehringer Ingelheim

Educational cancer slide kits

NSCLC Slide Kit

 

 

Boehringer Ingelheim offers slide kits suitable as teaching and learning aids for reviewing the fundamentals of cancer. The NSCLC slide kit outlines the epidemiology, pathology, clinical features, and risk factors of the disease.

memo inOncology SPECIAL ISSUE congress reports

Congress Report Special Issue Boeringher Ingelheim

Boehringer Ingelheim supports the Springer “memo inOncology SPECIAL ISSUE” congress report series with an unrestricted educational grant. Each issue summarises the latest findings in lung cancer to come out of a major international congress. Check the homepage to check out the archive, and access Spanish and Mandarin editions. Or download recent issues here!

WCLC 2016

ESMO 2016

ASCO 2016

The European Society for Medical Oncology (ESMO) wishes to thank Boehringer Ingelheim for making this content available.

ESMO only accepts content from third parties after careful evaluation of its educational and scientific relevance to the ESMO target audience. Eligible material should meet the essential criterion of non-promotional intent. Such material may be published in other resources, but the content donor has given permission to ESMO for use in OncologyPRO.